Value
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 3.1 |
| P/S | 5.1 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 2.9 |
| PEG | 3.7 |
| Analyst target | 5.0 |
- ▸Forward P/E: 36.6x
- ▸PEG: 2.93
ILMN · Why this verdict
Why Illumina (ILMN) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.2/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Four consecutive earnings beats averaging nearly 13% above consensus, best-in-class margins, a 34% return on equity, and a near-perfect financial health score make the quality case compelling — but revenue heavily concentrated in a single technology segment, reliance on single-source suppliers, and a forward earnings multiple above 28 times leave the risk/reward thin at the current price with the stock already past its analyst-derived target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Net margins of 19%, a return on equity of 34%, and a financial health score of 8 out of 9 reflect a business with strong profitability, sound balance sheet management, and operating efficiency that ranks best-in-class relative to peers. Quality | Return on equity remains above 25% and net margins hold above 15% over the next four reported quarters, sustaining the quality premium. | ↑Improving |
| CounterThe combined growth and profitability score (Rule of 40 at 24) falls below the 40-point threshold typically associated with software businesses able to sustain premium multiples, suggesting the quality metrics may not be sufficient to justify the current valuation without re-acceleration in revenue growth. | ||
The company has beaten consensus earnings estimates in each of the last four consecutive quarters, with average outperformance of nearly 13% above expectations — a consistent pattern of delivering results above what analysts anticipated, most recently in April 2026. Catalyst | EPS continues to exceed consensus estimates in each of the next two quarters, sustaining the track record of consistent outperformance. | ↓Deteriorating |
| CounterThe margin of outperformance has narrowed from over 17% in the oldest of the four quarters to 9% in the most recent, which may indicate that estimates are catching up to the company's actual trajectory — reducing the runway for further positive surprises. | ||
Sequencing-related revenue represents 92% of total revenue, creating material concentration risk — a slowdown, competitive disruption, or technology transition in that single segment could materially impair the overall business even if other areas perform well. Bear case | Revenue from segments outside the dominant product line grows to represent at least 15% of total revenue over 12 months, meaningfully reducing the concentration. | ↓Deteriorating |
| CounterHigh concentration in one category can also reflect genuine market leadership in that category; if the underlying sequencing market continues to grow, concentration in the leading product may be a strength rather than a vulnerability. | ||
A forward price-to-earnings ratio of 28 times and a price-to-earnings-to-growth ratio of 2.93 place the stock at a premium that leaves little room for estimate disappointment — the current price has already moved past the analyst-derived target, and the risk/reward geometry does not support the current entry. Key risks | The forward multiple compresses below 20 times as earnings growth accelerates to close the gap between price and intrinsic value, restoring a more balanced risk/reward. | ↓Deteriorating |
| CounterPremium multiples can be sustained or expanded when earnings consistently exceed expectations — four straight beats suggest the company may be under-promising and over-delivering, which can justify a persistent multiple premium above what the trailing growth rate alone would imply. | ||
Net margins of 19%, a return on equity of 34%, and a financial health score of 8 out of 9 reflect a business with strong profitability, sound balance sheet management, and operating efficiency that ranks best-in-class relative to peers.
↑ImprovingQuality
- Expectation
- Return on equity remains above 25% and net margins hold above 15% over the next four reported quarters, sustaining the quality premium.
CounterThe combined growth and profitability score (Rule of 40 at 24) falls below the 40-point threshold typically associated with software businesses able to sustain premium multiples, suggesting the quality metrics may not be sufficient to justify the current valuation without re-acceleration in revenue growth.
The company has beaten consensus earnings estimates in each of the last four consecutive quarters, with average outperformance of nearly 13% above expectations — a consistent pattern of delivering results above what analysts anticipated, most recently in April 2026.
↓DeterioratingCatalyst
- Expectation
- EPS continues to exceed consensus estimates in each of the next two quarters, sustaining the track record of consistent outperformance.
CounterThe margin of outperformance has narrowed from over 17% in the oldest of the four quarters to 9% in the most recent, which may indicate that estimates are catching up to the company's actual trajectory — reducing the runway for further positive surprises.
Sequencing-related revenue represents 92% of total revenue, creating material concentration risk — a slowdown, competitive disruption, or technology transition in that single segment could materially impair the overall business even if other areas perform well.
↓DeterioratingBear case
- Expectation
- Revenue from segments outside the dominant product line grows to represent at least 15% of total revenue over 12 months, meaningfully reducing the concentration.
CounterHigh concentration in one category can also reflect genuine market leadership in that category; if the underlying sequencing market continues to grow, concentration in the leading product may be a strength rather than a vulnerability.
A forward price-to-earnings ratio of 28 times and a price-to-earnings-to-growth ratio of 2.93 place the stock at a premium that leaves little room for estimate disappointment — the current price has already moved past the analyst-derived target, and the risk/reward geometry does not support the current entry.
↓DeterioratingKey risks
- Expectation
- The forward multiple compresses below 20 times as earnings growth accelerates to close the gap between price and intrinsic value, restoring a more balanced risk/reward.
CounterPremium multiples can be sustained or expanded when earnings consistently exceed expectations — four straight beats suggest the company may be under-promising and over-delivering, which can justify a persistent multiple premium above what the trailing growth rate alone would imply.
Per-dimension breakdown
Quality
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 5.5 |
| Gross margin | 9.5 |
| Op margin | 8.0 |
| Net margin | 9.9 |
| Current ratio | 8.9 |
| FCF quality | 6.8 |
| Moat | 7.1 |
| Rule of 40 | 3.0 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 32%
- ▸Strong margins: 20%
- ▸Rule of 40: 23 (fail)
- ▸Strong Piotroski F-Score: 9/9
Growth
6.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.6 |
| EPS growth | 10.0 |
Momentum
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.9 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 5.4 |
- ▸Uptrend pullback (RSI 36) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.8 |
| Analyst rating | 5.0 |
| Price target | 7.2 |
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Heavy insider selling — $288,195,103 (0.841% of mkt cap)
Peer rank
4.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.3 |
| quality rank | 8.4 |
| growth rank | 1.6 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 9.5 |
| 52w position | 4.6 |
| gap | 5.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.8 |
| days to cover | 9.0 |
| volatility | 0.0 |
| put call | 4.7 |
| implied vol | 2.1 |
| max pain risk | 3.0 |
| beta | 5.2 |
| debt equity | 6.6 |
- ▸High IV: 68%
- ▸Above max pain $145
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 6.4 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=+2|ENTRY_STICKY:WITHIN_BANDPassed (4)
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:91d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:3.7<4.5
- ASYMMETRY:0.3<1.5@spot
- INSIDER:0.84%=HEAVY
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.26
Upside
+3.9%
Downside
15.0%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeTemporary headwind — High quality (7.9) with weak momentum (3.7)
SuitabilityAggressive — Beta 1.45>1.3
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: NEWS_EVENTS:NONE_RECENT. Top dim: Quality at 7.9; weakest: Insider at 3.0. No conviction either direction.
The strongest dimensions are Quality at 7.9, Technical at 7.3, and Growth at 6.8; the weakest are Insider at 3.0, Value at 3.4, and Momentum at 3.7. The V9 engine flagged 3 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.26 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Four Quarter Beat Streak
Trip ifEPS falls below consensus in 2 consecutive quarters, breaking the four-quarter beat streak.
- P2High Quality Margins And Returns
Trip ifReturn on equity falls below 15% for 2 consecutive reported quarters, a material decline from the current 34% level.
- P3Product Revenue Concentration Risk
Trip ifRevenue from non-sequencing segments grows to represent more than 20% of total revenue, reducing sequencing concentration below 80%.
- P4Rich Valuation Limits Upside
Trip ifForward price-to-earnings ratio compresses below 20x, indicating the valuation premium has meaningfully resolved.